Update on the treatment of type 2 diabetes mellitus
Open Access
- 1 January 2016
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 7 (17), 354-95
- https://doi.org/10.4239/wjd.v7.i17.354
Abstract
To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving near-normal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifestyle changes. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on the characteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.Keywords
This publication has 100 references indexed in Scilit:
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 DiabetesDiabetes Care, 2007
- Effect of renal impairment on the pharmacokinetics of exenatideBritish Journal of Clinical Pharmacology, 2007
- Activation of Peroxisome Proliferator-Activated Receptor γ (PPARγ) by Rosiglitazone Suppresses Components of the Insulin-Like Growth Factor Regulatory System in Vitro and in VivoEndocrinology, 2007
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trialDiabetes, Obesity and Metabolism, 2007
- A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyDiabetologia, 2006
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia, 2006
- Inflammation and insulin resistanceJCI Insight, 2006
- Role of AMP-activated protein kinase in mechanism of metformin actionJCI Insight, 2001
- MiglitolDrugs, 2000